EXACT SCIENCES CORP. overview

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results PR Newswire MADISON, Wis., Jan. 7, 2024 Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion , submits next-generation Cologuard ® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5 - $647.5 million , an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0 - $487.0 million and...

Exact Sciences to participate in J.P. Morgan Healthcare Conference PR Newswire MADISON, Wis., Jan. 2, 2024 MADISON, Wis. , Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 8, 2024 at 2:15...

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings PR Newswire MADISON, Wis., Dec. 7, 2023 MADISON, Wis. , Dec. 7, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates...

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients PR Newswire MADISON, Wis., Nov. 30, 2023 Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score ® results to refine distant recurrence risk estimates New concordance analysis supporting the generation of Oncotype DX ® results from core needle biopsy to personalize treatment...

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy PR Newswire MADISON, Wis., Nov. 17, 2023 Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis. , Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of...

Exact Sciences Announces Third-Quarter 2023 Results PR Newswire MADISON, Wis., Nov. 1, 2023 Reports record revenue, delivers more than a million test results, raises full-year guidance Third -quarter 2023 highlights Total third quarter revenue of $628 million , an increase of 20%, or 23% on a core revenue basis Delivered more than 1 million test results, including a record for Cologuard® and Oncotype DX® tests Full-year 2023 revenue and adjusted EBITDA guidance midpoints raised by $28 million...

Exact Sciences to participate in November investor conferences PR Newswire MADISON, Wis., Nov. 1, 2023 MADISON, Wis. , Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Stifel Healthcare Conference, New York Fireside chat on Tuesday, November 14, 2023 at 10:20 a.m. ET Jefferies London...

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection PR Newswire MADISON, Wis., Oct. 22, 2023 American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for next-generation Cologuard test expected to minimize...